Next-generation drugs inclusion to the South's HIV/AIDS programs: The Brazilian experience on third-line drugs

Carla Zaire (1) , Benjamin Coriat (1) , Lia Hansenclever (2)

1 CEPN - Centre d'Economie de l'Université Paris Nord
2 IE / UFRJ - Instituto de Economia da Universidade Federal do Rio de Janeiro

Brazil, which has one of the largest patients cohort (315 000 people on TARV) and one of the oldest, is the first country in the south to confront the challenge of third-line treatments distribution. Currently, the National Program HIV/AIDS distributes six third-line ARV (Darunavir, enfuvirtide, étravirine, raltégravir, tipranavir and maraviroc) to the patients in virological treatment failure. Our research is interested in the evolution of the purchase price of each ARV and the impact of third-lines on the total budget devoted to acquisition of ARVs.

Mots clés: third-line antiretrovirals; purchase price; acquisition of ARV

Domaines: Santé publique et épidémiologie

Carla Zaire, Benjamin Coriat, Lia Hansenclever. Next-generation drugs inclusion to the South's HIV/AIDS programs: The Brazilian experience on third-line drugs. Journal of the International AIDS Society, 2013, 16 (1), ⟨10.7448/IAS.16.2.18685⟩. ⟨hal-01493257⟩